Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.92 +0.48 (+3.86%)

Streaming Delayed Price Updated: 2:07 PM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

21 22 Next >

Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit? ↗

June 21, 2023

There's more than one reason to sell a stock while buying another.

Via The Motley Fool

Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money. ↗

June 20, 2023

One of these stocks has already doubled this year.

Via The Motley Fool

Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why. ↗

June 19, 2023

It has quite a few of the core ingredients for success in biopharma.

Via The Motley Fool

Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy ↗

June 18, 2023

Success could be in the DNA of the Ark Invest founder.

Via The Motley Fool

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

What 10 Analyst Ratings Have To Say About Intellia Therapeutics ↗

June 13, 2023

Via Benzinga

Where Intellia Therapeutics Stands With Analysts ↗

June 13, 2023

Via Benzinga

Why Is Intellia (NTLA) Stock Up 5% Today? ↗

June 12, 2023

NTLA stock is trending on social media and is up over 5%. The drugmaker reported new, positive results from its gene-edited treatment.

Via InvestorPlace

Can This Gene-Editing Stock Deliver 10X Returns? ↗

June 08, 2023

Buying shares of Intellia Therapeutics might be a smart move.

Via The Motley Fool

3 Cathie Wood Investments That Could Deliver Superior Returns ↗

June 17, 2023

These three stocks fit Wood's profile for big-time growth.

Via The Motley Fool

2 Short-Squeeze Candidates That Could Go Parabolic ↗

June 15, 2023

Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.

Via The Motley Fool

2 Growth Stocks Cathie Wood Is Buying Hand Over Fist ↗

June 15, 2023

The fund manager most famous for innovation-focused investing thinks these two stocks have what it takes to produce big gains.

Via The Motley Fool

Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst ↗

June 12, 2023

Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing

Via Benzinga

Why Are Cruise Stocks CCL, RCL, NCLH Up Today? ↗

June 12, 2023

Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details!

Via InvestorPlace

BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing ↗

June 12, 2023

Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday.

Via InvestorPlace

12 Analysts Have This to Say About Intellia Therapeutics ↗

May 05, 2023

Via Benzinga

Intellia Therapeutics: Q1 Earnings Insights ↗

May 04, 2023

Via Benzinga

Intellia Therapeutics's Earnings Outlook ↗

May 03, 2023

Via Benzinga

Intellia Therapeutics Surges As CRISPR Gene-Editing Drug Potentially Cures Swelling Disease ↗

June 12, 2023

The company is testing a treatment for hereditary angioedemia, a potentially fatal swelling disorder.

Via Investor's Business Daily

Why Intellia Therapeutics Stock Is Rising Monday ↗

June 12, 2023

Intellia Therapeutics Inc (NASDAQ: NTLA) shares are trading higher Monday after the clinical-stage genome editing company announced data for its treatment for people living with hereditary angioedema...

Via Benzinga

Chinook Therapeutics, Oracle And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

June 12, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. Chinook Therapeutics, Inc. (NASDAQ: KDNY) shares jumped 66.8% to $40.01 in...

Via Benzinga

Wall Street Says These 2 Stocks May Double. Should You Buy Them? ↗

June 05, 2023

Both of these stocks have declined over the past year.

Via The Motley Fool

Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You? ↗

May 16, 2023

The Ark Invest CEO is betting on rebounds for these beaten-down stocks.

Via The Motley Fool

Why Intellia Therapeutics Shares Are Surging Today ↗

May 04, 2023

Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares are up Thursday as its Q1 results surpassed estimates. The company looks forward to sharing new interim data from NTLA-2001 and NTLA-2002...

Via Benzinga

The 3 Most Promising Gene Editing Stocks to Buy in 2023 ↗

April 28, 2023

Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.

Via InvestorPlace

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

April 28, 2023

Via The Motley Fool

3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat ↗

April 25, 2023

Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat.

Via InvestorPlace

3 High-Growth Biotech Stocks Poised for Success in 2023 ↗

April 18, 2023

If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity

Via InvestorPlace

2 Monster Growth Stocks That Can Double in Value, According to Wall Street ↗

April 14, 2023

These stocks have some promising growth opportunities, but they also come with a fair amount of risk.

Via The Motley Fool

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today? ↗

April 13, 2023

While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.

Via InvestorPlace

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Starting at /week.